We are a late-stage biopharmaceutical company focused on developing novel therapies for serious immune mediated diseases.
Through our scientific platform, our strategy is to build and advance a pipeline of best-in-class, oral drug candidates to address serious needs in immune-mediated diseases. If successful, our medicines have the potential to bring significant therapeutic benefits, limit unintended side effects, improve quality of life for patients and over time modify the course of disease. We aim to do this by delivering drugs that have an optimized risk benefit profile with better quality of life and convenience.
Our wholly owned BTK inhibitor, rilzabrutinib, is currently being developed in two disease indications, pemphigus and immune thrombocytopenia, and plans to initiate a Phase 2 clinical trial in patients with IgG4-related diseases. PRN2246/SAR442168, our BTK inhibitor for central nervous system diseases, is currently being developed by Sanofi for multiple sclerosis. PRN473 Topical, a reversible covalent BTK inhibitor will be evaluated in Phase 1 clinical trials for immune-mediated diseases. We will continue to expand development of our molecules and pipeline and may strategically use collaborations and partnerships as a means to maximizing the value of those assets.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Press ReleasesView All
from 4:00 PM to 6:00 PM EDT
3:00 PM EDT
10:00 AM EST